Clinical significance of zinc finger E-box binding homeobox 1 (ZEB1) in human gastric cancer

Journal of Surgical Oncology

Volumn 106, Issue 3, 2012, Pages 280-285

  Okugawa, Yoshinaga ^a,b   Toiyama, Yuji ^a   Tanaka, Koji ^a   Matsusita, Kohei ^a   Fujikawa, Hiroyuki ^a   Saigusa, Susumu ^a   Ohi, Masaki ^a   Inoue, Yasuhiro ^a   Mohri, Yasuhiko ^a   Uchida, Keiichi ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Mie Prefectural General Medical Center   (Japan)

Author keywords

gastric cancer; peritoneal dissemination; zinc finger E box binding homeobox 1

Indexed keywords

MESSENGER RNA; UNCLASSIFIED DRUG; ZINC FINGER E BOX BINDING HOMEOBOX 1 PROTEIN; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER TISSUE; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTRECTOMY; GASTRIC MUCOSA; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PERITONEUM; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84864656811     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22142     Document Type: Article

References (38)

1. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
2. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
3. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
4. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
5. Duarte I, Llanos O,: Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981; 12: 237-242.
6. Maehara Y, Moriguchi S, Kakeji Y, et al.: Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991; 110: 820-823.
7. Sugarbaker PH, Yonemura Y,: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncology 2000; 58: 96-107.
8. Gretschel S, Siegel R, Estevez-Schwarz L, et al.: Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 2006; 93: 1530-1535.
9. Bonenkamp JJ, Sasako M, Hermans J, et al.: Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology 2001; 48: 1219-1221.
10. Thiery JP, Sleeman JP,: Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
11. Thiery JP,: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746.
12. Allan GJ, Beattie J, Flint DJ,: Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol 2008; 199: 155-164.
13. Sleeman JP,: The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 2000; 157: 55-81.
14. Christiansen JJ, Rajasekaran AK,: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.
15. Klymkowsky MW, Savagner P,: Epithelial-mesenchymal transition: A cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588-1593.
16. Spaderna S, Schmalhofer O, Hlubek F, et al.: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131: 830-840.
17. Eger A, Aigner K, Sonderegger S, et al.: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385.
18. Ohira T, Gemmill RM, Ferguson K, et al.: WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 2003; 100: 10429-10434.
19. Chua HL, Bhat-Nakshatri P, Clare SE, et al.: NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. Oncogene 2007; 26: 711-724.
20. Graham TR, Zhau HE, Odero-Marah VA, et al.: Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68: 2479-2488.
21. Richer JK, Jacobsen BM, Manning NG, et al.: Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277: 5209-5218.
22. Aigner K, Descovich L, Mikula M, et al.: The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett 2007; 581: 1617-1624.
23. Aigner K, Dampier B, Descovich L, et al.: The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007; 26: 6979-6988.
24. Hu F, Wang C, Du J, et al.: DeltaEF1 promotes breast cancer cell proliferation through down-regulating p21 expression. Biochim Biophys Acta 2010; 1802: 301-312.
25. Takeyama Y, Sato M, Horio M, et al.: Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage- independent cell growth of lung cancer cells. Cancer Lett 2010; 296: 216-224.
26. Spoelstra NS, Manning NG, Higashi Y, et al.: The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 2006; 66: 3893-3902.
27. Singh M, Spoelstra NS, Jean A, et al.: ZEB1 expression in type I vs type II endometrial cancers: A marker of aggressive disease. Mod Pathol 2008; 21: 912-923.
28. Krishnamachary B, Zagzag D, Nagasawa H, et al.: Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006; 66: 2725-2731.
29. Anose BM, LaGoo L, Schwendinger J,: Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells. Adv Exp Med Biol 2008; 617: 541-546.
30. Kawajiri H, Yashiro M, Shinto O, et al.: A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 2008; 14: 2850-2860.
31. Nishimura S, Chung YS, Yashiro M, et al.: Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 1996; 74: 1406-1412.
32. Yashiro M, Chung YS, Nishimura S, et al.: Establishment of two new scirrhous gastric cancer cell lines: Analysis of factors associated with disseminated metastasis. Br J Cancer 1995; 72: 1200-1210.
33. Bernstein LR, Liotta LA,: Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 1994; 6: 106-113.
34. Shino Y, Watanabe A, Yamada Y, et al.: Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995; 76: 2193-2201.
35. Yonemura Y, Endou Y, Kimura K, et al.: Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000; 6: 4234-4242.
36. Derksen PW, Liu X, Saridin F, et al.: Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10: 437-449.
37. Smit MA, Geiger TR, Song JY, et al.: A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol 2009; 29: 3722-3737.
38. Eccles SA, Welch DR,: Metastasis: Recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757.